NRSN (NRSN) Stock Price & Analysis
NRSN (NRSN) fell 8.08% to USD 0.6 as of July 25, 2026 at 08:14 UTC, according to Nexqual real-time market data.
NRSN last closed at USD 0.66; the session ranged USD 0.59–0.72 on volume of 160,144 shares. Market capitalization is $21.74M, with a 52-week range of USD 0.58–2.09 (NCM). Source: Nexqual, July 25, 2026 at 08:14 UTC.
Key Statistics (as of July 25, 2026 at 08:14 UTC)
| Price | USD 0.6 |
|---|---|
| Change | ▼ 8.08% (down) |
| Previous Close | USD 0.66 |
| Open | USD 0.72 |
| Day Range | USD 0.59 – 0.72 |
| 52-Week Range | USD 0.58 – 2.09 |
| Volume | 160,144 shares |
| Market Cap | $21.74M |
| Exchange | NCM |
Technical Analysis (NRSN)
Nexqual's technical model rates NRSN "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 08:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.75 (oversold) |
| vs SMA50 | Below (USD 0.75) |
| MACD | -0.03 (negative) |
Analyst Ratings (NRSN)
Wall Street analysts rate NRSN "Strong Buy" based on 3 analysts, with a mean price target of USD 6.5 (range USD 3–9), per Nexqual as of July 25, 2026 at 08:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6.5 |
| High Target | USD 9 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NRSN)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Financials & Fundamentals (NRSN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -2174.98% |
| Current Ratio | 0.31 |
| Total Cash | $166,000 |
| Total Debt | $170,000 |
| Free Cash Flow | $-3.87M |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Financial Health Score (NRSN)
Nexqual rates NRSN's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $166K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -2175%, ROA -247.3% |
Ownership (NRSN)
| Insider Ownership | +32.30% |
|---|---|
| Institutional Ownership | +0.96% |
| Shares Outstanding | 36.10M |
| Float | 23.34M |
| Short % of Float | +1.96% |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Leadership (NRSN)
NRSN is led by Alon Ben-Noon (age 46), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 08:14 UTC.
| Co-Founder, CEO & Director | Alon Ben-Noon (age 46) |
|---|---|
| Chief Financial Officer | Or Eisenberg (age 44) |
| Chief Technology Officer | Niva Russek-Blum (age 46) |
Major Backers & Investors (NRSN)
Notable institutional backers of NRSN include Yorkville Advisors Global, LP, UBS Group AG, Independent Advisor Alliance, according to Nexqual as of July 25, 2026 at 08:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yorkville Advisors Global, LP | 0.24% |
| UBS Group AG | 0.15% |
| Independent Advisor Alliance | 0.15% |
| Two Sigma Investments, LP | 0.14% |
Source: Nexqual, July 25, 2026 at 08:14 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| IMMX | Immix Biopharma, Inc. | USD 8.52 | ▼ 9.46% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| BTTX | Better Therapeutics, Inc. | USD 0 | ▲ 0% |
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:14 UTC. This page is informational and not investment advice.